(NASDAQ: BBNX) Beta Bionics's forecast annual revenue growth rate of 31.73% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.53%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Beta Bionics's revenue in 2026 is $110,238,000.On average, 13 Wall Street analysts forecast BBNX's revenue for 2026 to be $6,075,987,113, with the lowest BBNX revenue forecast at $5,720,830,404, and the highest BBNX revenue forecast at $6,452,087,819. On average, 13 Wall Street analysts forecast BBNX's revenue for 2027 to be $8,217,622,175, with the lowest BBNX revenue forecast at $7,083,527,037, and the highest BBNX revenue forecast at $9,153,417,770.
In 2028, BBNX is forecast to generate $11,456,366,168 in revenue, with the lowest revenue forecast at $10,004,991,761 and the highest revenue forecast at $13,101,138,330.